talquetamab
janssen
['mmsm', 'monumental-i', 'multiple myeloma', 'monumental,(-monumental1),(-monumental 1),(-monumental-1)', 'talquetamab']
the use of two separate recommended phase 2 doses of talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma. #mmsm #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.